EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access

Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults

Mark R Litzow, Zhuoxin Sun, Ryan J Mattison, Elisabeth M Paietta, Kathryn G Roberts, Yanming Zhang, Janis Racevskis, Hillard M Lazarus, Jacob M Rowe, Daniel A Arber, Matthew J Wieduwilt, Michaela Liedtke und 30 weitere

New England Journal of Medicine · 25.07.2024 · 391 (4) · 320-333

DOI: 10.1056/nejmoa2312948 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 25.07.2024. Verfasst von Mark R Litzow und 41 weiteren Autor:innen. Beteiligte Einrichtung: From the Mayo Clinic, Rochester, MN (M.R.L., C.L.W., M.A.E.); Dana-Farber Cancer Institute, Boston (Z.S., D.J.D., R.M.S.); the University of Wisconsi…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasm, Residual, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 301-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS, ECOG-ACRIN Cancer Research Group.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasm, ResidualPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAdultAgedFemaleHumansMaleMiddle AgedAntibodies, BispecificAntineoplastic Combined Chemotherapy ProtocolsConsolidation ChemotherapyDisease-Free SurvivalInduction ChemotherapyKaplan-Meier EstimateRecurrenceRemission InductionSurvival Analysis

Substanzen

Antibodies, BispecificAntineoplastic Agentsblinatumomab

Autor:innen und Institutionen

  • From the Mayo Clinic, Rochester, MN (M.R.L., C.L.W., M.A.E.); Dana-Farber Cancer Institute, Boston (Z.S., D.J.D., R.M.S.); the University of Wisconsin Carbone Cancer Center, Madison (R.J.M.), and the Medical College of…

ORCID-Profile: Charles G Mullighan

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • ECOG-ACRIN Cancer Research Group
  • NIGMS NIH HHS

Zitieren

APA

Litzow, M. R., Sun, Z., Mattison, R. J., Paietta, E. M., Roberts, K. G., Zhang, Y., Racevskis, J., Lazarus, H. M., Rowe, J. M., Arber, D. A., Wieduwilt, M. J., Liedtke, M., Bergeron, J., Wood, B. L., Zhao, Y., Wu, G., Chang, T. C., Zhang, W., Pratz, K. W., …, & Tallman, M. S. (2024). Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. New England Journal of Medicine, 391(4), 320-333. https://doi.org/10.1056/nejmoa2312948

Vancouver

Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, et al. Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. New England Journal of Medicine. 2024;391(4):320-333. doi:10.1056/nejmoa2312948

BibTeX
@article{Litzow2024,
  author = {Litzow, Mark R and Sun, Zhuoxin and Mattison, Ryan J and Paietta, Elisabeth M and Roberts, Kathryn G and Zhang, Yanming and Racevskis, Janis and Lazarus, Hillard M and Rowe, Jacob M and Arber, Daniel A and Wieduwilt, Matthew J and Liedtke, Michaela and Bergeron, Julie and Wood, Brent L and Zhao, Yaqi and Wu, Gang and Chang, Ti-Cheng and Zhang, Wenchao and Pratz, Keith W and Dinner, Shira N and Frey, Noelle and Gore, Steven D and Bhatnagar, Bhavana and Atallah, Ehab L and Uy, Geoffrey L and Jeyakumar, Deepa and Lin, Tara L and Willman, Cheryl L and DeAngelo, Daniel J and Patel, Shejal B and Elliott, Michelle A and Advani, Anjali S and Tzachanis, Dimitrios and Vachhani, Pankit and Bhave, Rupali R and Sharon, Elad and Little, Richard F and Erba, Harry P and Stone, Richard M and Luger, Selina M and Mullighan, Charles G and Tallman, Martin S},
  title = {Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {4},
  pages = {320--333},
  doi = {10.1056/nejmoa2312948}
}
Kostenlos starten →